Use of Anti-EGFR Aptamer Construct GR20hh for Controlled Delivery of Doxorubicin into Patient-Derived Glioblastoma Cells.

Autor: Ivanov, B. M., Antipova, O. M., Sliman, Ya. A., Samoylenkova, N. S., Pronin, I. N., Pavlova, G. V., Kopylov, A. M.
Předmět:
Zdroj: Neuroscience & Behavioral Physiology; Jul2024, Vol. 54 Issue 6, p923-928, 6p
Abstrakt: We report here a study of the potential for controlled delivery of doxorubicin (DOX) into glioblastoma (GB) cells as part of a non-covalent construct with an EGFR-specific DNA aptamer by intercalation into an artificially created duplex. The construct consists of the previously described DNA aptamer GR20 (46 nucleotides) extended by 18 nucleotides from the 3' end (GR20h), and hybridized with a complementary DNA oligonucleotide (h). The duplex assembles efficiently and the resulting GR20hh design is stable at 37°C, Tm = 59°C. DOX is intercalated into the structure. Application of the xCelligence method with original data processing showed that DOX added to cell cultures as part of the non-covalent construct GR20hh–DOX retained cytotoxic properties, though the kinetics of the action of the complex on GB cells were fundamentally different from the action of free DOX. This unique approach and the data obtained using it open up opportunities for regulating the cytotoxic activity of DOX and developing methods for targeting GB cells. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index